While there are a variety of mechanisms involved in how tumor cells evades anti-tumor immunity as a barrier to cancer immunotherapy [5, 28, 33-36], K3-SPG is able to overcome one of these, at least in part by K3-SPG-induced immunogenic tumor cell death, potentially increasing neo- and/or subdominant tumor antigen-specific CD8+ T cells responses. Here, CD8A is linked to cancer.